ES2358846T3 - Medios y método para predecir diabetes tipo ii. - Google Patents

Medios y método para predecir diabetes tipo ii. Download PDF

Info

Publication number: ES2358846T3
Authority: ES; Spain
Prior art keywords: acid; cis; diabetes; predisposition; metabolites
Prior art date: 2006-03-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES07727167T

Other languages

English (en)

Spanish (es)

Inventor

Bianca Bethan

Kristina Busch

Jan Wiemer

Martijn Gipmans

Edgar Leibold

Jochen Spranger

Thomas Bobbert

Andreas Friedrich Hermann Pfeiffer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

BASF Metabolome Solutions GmbH

Original Assignee

Metanomics GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-24

Filing date

2007-03-21

Publication date

2011-05-16

2007-03-21 Application filed by Metanomics GmbH filed Critical Metanomics GmbH

2011-05-16 Application granted granted Critical

2011-05-16 Publication of ES2358846T3 publication Critical patent/ES2358846T3/es

Status Active legal-status Critical Current

2027-03-21 Anticipated expiration legal-status Critical

Links

238000000034 method Methods 0.000 title claims abstract description 65
208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 51
239000002207 metabolite Substances 0.000 claims abstract description 168
239000000523 sample Substances 0.000 claims abstract description 33
238000012360 testing method Methods 0.000 claims abstract description 26
REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 claims abstract description 18
BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 claims abstract description 10
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 10
229940108623 eicosenoic acid Drugs 0.000 claims abstract description 10
BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 claims abstract description 10
MPCAJMNYNOGXPB-SLPGGIOYSA-N 1,5-anhydro-D-glucitol Chemical compound OC[C@H]1OC[C@H](O)[C@@H](O)[C@@H]1O MPCAJMNYNOGXPB-SLPGGIOYSA-N 0.000 claims abstract description 9
210000002966 serum Anatomy 0.000 claims abstract description 5
239000013074 reference sample Substances 0.000 claims abstract description 4
238000009534 blood test Methods 0.000 claims abstract description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 42
239000008103 glucose Substances 0.000 claims description 33
-1 preferably Substances 0.000 claims description 33
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 32
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 30
238000004949 mass spectrometry Methods 0.000 claims description 29
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 26
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 26
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 24
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 24
WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 23
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 22
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 22
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 20
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 19
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 19
239000004474 valine Substances 0.000 claims description 19
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 18
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 18
229910019142 PO4 Inorganic materials 0.000 claims description 18
235000010323 ascorbic acid Nutrition 0.000 claims description 18
229960005070 ascorbic acid Drugs 0.000 claims description 18
239000011668 ascorbic acid Substances 0.000 claims description 18
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 claims description 18
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 17
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 17
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 17
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 17
235000004279 alanine Nutrition 0.000 claims description 17
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 17
235000017471 coenzyme Q10 Nutrition 0.000 claims description 17
229940110767 coenzyme Q10 Drugs 0.000 claims description 17
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 17
235000018417 cysteine Nutrition 0.000 claims description 17
238000004817 gas chromatography Methods 0.000 claims description 17
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 17
235000002374 tyrosine Nutrition 0.000 claims description 17
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 16
235000020669 docosahexaenoic acid Nutrition 0.000 claims description 16
229940090949 docosahexaenoic acid Drugs 0.000 claims description 16
229960000310 isoleucine Drugs 0.000 claims description 16
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 16
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 14
235000021353 Lignoceric acid Nutrition 0.000 claims description 14
CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 claims description 14
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 14
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 14
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 14
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 14
235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 14
229960005135 eicosapentaenoic acid Drugs 0.000 claims description 14
FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 claims description 14
238000004811 liquid chromatography Methods 0.000 claims description 14
229940049920 malate Drugs 0.000 claims description 14
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 14
239000010452 phosphate Substances 0.000 claims description 14
235000013930 proline Nutrition 0.000 claims description 14
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 13
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 13
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 13
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 13
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 13
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 13
239000004472 Lysine Substances 0.000 claims description 13
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 13
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 13
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 13
239000004473 Threonine Substances 0.000 claims description 13
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 13
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 13
229940087168 alpha tocopherol Drugs 0.000 claims description 13
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 13
235000020661 alpha-linolenic acid Nutrition 0.000 claims description 13
229940114079 arachidonic acid Drugs 0.000 claims description 13
235000021342 arachidonic acid Nutrition 0.000 claims description 13
229960002173 citrulline Drugs 0.000 claims description 13
235000013477 citrulline Nutrition 0.000 claims description 13
235000020778 linoleic acid Nutrition 0.000 claims description 13
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 13
229960004488 linolenic acid Drugs 0.000 claims description 13
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 13
229960000984 tocofersolan Drugs 0.000 claims description 13
229940116269 uric acid Drugs 0.000 claims description 13
235000004835 α-tocopherol Nutrition 0.000 claims description 13
239000002076 α-tocopherol Substances 0.000 claims description 13
239000004471 Glycine Substances 0.000 claims description 12
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 12
239000004202 carbamide Substances 0.000 claims description 12
150000002632 lipids Chemical class 0.000 claims description 12
229930182817 methionine Natural products 0.000 claims description 12
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 12
XEZVDURJDFGERA-UHFFFAOYSA-N tricosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)=O XEZVDURJDFGERA-UHFFFAOYSA-N 0.000 claims description 12
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 11
QUKRTJQSGPLQKQ-UHFFFAOYSA-N 5-methylsulfonyl-3h-1,3-benzoxazol-2-one Chemical compound CS(=O)(=O)C1=CC=C2OC(=O)NC2=C1 QUKRTJQSGPLQKQ-UHFFFAOYSA-N 0.000 claims description 11
GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 11
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 11
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 11
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 11
235000021360 Myristic acid Nutrition 0.000 claims description 11
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 11
235000021314 Palmitic acid Nutrition 0.000 claims description 11
235000021355 Stearic acid Nutrition 0.000 claims description 11
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 11
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 11
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 11
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 11
SECPZKHBENQXJG-BQYQJAHWSA-N palmitelaidic acid Chemical compound CCCCCC\C=C\CCCCCCCC(O)=O SECPZKHBENQXJG-BQYQJAHWSA-N 0.000 claims description 11
235000019161 pantothenic acid Nutrition 0.000 claims description 11
229940055726 pantothenic acid Drugs 0.000 claims description 11
239000011713 pantothenic acid Substances 0.000 claims description 11
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 11
235000008729 phenylalanine Nutrition 0.000 claims description 11
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 11
210000002381 plasma Anatomy 0.000 claims description 11
239000008117 stearic acid Substances 0.000 claims description 11
229960004295 valine Drugs 0.000 claims description 11
JPIJQSOTBSSVTP-GBXIJSLDSA-N D-threonic acid Chemical compound OC[C@@H](O)[C@H](O)C(O)=O JPIJQSOTBSSVTP-GBXIJSLDSA-N 0.000 claims description 10
229940109239 creatinine Drugs 0.000 claims description 10
150000001982 diacylglycerols Chemical class 0.000 claims description 10
150000003904 phospholipids Chemical class 0.000 claims description 10
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 10
229960004441 tyrosine Drugs 0.000 claims description 10
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 9
150000001413 amino acids Chemical class 0.000 claims description 9
210000004369 blood Anatomy 0.000 claims description 9
239000008280 blood Substances 0.000 claims description 9
235000012000 cholesterol Nutrition 0.000 claims description 9
229960000367 inositol Drugs 0.000 claims description 9
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 9
229960003136 leucine Drugs 0.000 claims description 9
229960003646 lysine Drugs 0.000 claims description 9
229940041290 mannose Drugs 0.000 claims description 9
229960005190 phenylalanine Drugs 0.000 claims description 9
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 9
RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 claims description 8
RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 claims description 8
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 8
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 8
229940024606 amino acid Drugs 0.000 claims description 8
235000001014 amino acid Nutrition 0.000 claims description 8
229960002433 cysteine Drugs 0.000 claims description 8
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 8
PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims description 8
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 7
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 7
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 7
229960003104 ornithine Drugs 0.000 claims description 7
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 7
235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 5
230000004102 tricarboxylic acid cycle Effects 0.000 claims description 5
230000004143 urea cycle Effects 0.000 claims description 5
239000003963 antioxidant agent Substances 0.000 claims description 4
230000003078 antioxidant effect Effects 0.000 claims description 4
235000006708 antioxidants Nutrition 0.000 claims description 4
150000004671 saturated fatty acids Chemical class 0.000 claims description 3
OOOOWWQUAMMOCL-FHAQVOQBSA-N (2s,3s)-2-amino-3-methylpentanoic acid;7,9-dihydro-3h-purine-2,6,8-trione Chemical compound CC[C@H](C)[C@H](N)C(O)=O.N1C(=O)NC(=O)C2=C1NC(=O)N2 OOOOWWQUAMMOCL-FHAQVOQBSA-N 0.000 claims description 2
206010012601 diabetes mellitus Diseases 0.000 description 82
230000007423 decrease Effects 0.000 description 56
230000033228 biological regulation Effects 0.000 description 32
229960001031 glucose Drugs 0.000 description 32
150000001875 compounds Chemical class 0.000 description 31
230000008859 change Effects 0.000 description 30
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 28
239000000126 substance Substances 0.000 description 28
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
201000010099 disease Diseases 0.000 description 22
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
238000003745 diagnosis Methods 0.000 description 20
239000000090 biomarker Substances 0.000 description 14
235000021317 phosphate Nutrition 0.000 description 13
102000004877 Insulin Human genes 0.000 description 12
108090001061 Insulin Proteins 0.000 description 12
229940125396 insulin Drugs 0.000 description 12
TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 12
238000000926 separation method Methods 0.000 description 11
238000000692 Student's t-test Methods 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
238000001514 detection method Methods 0.000 description 10
208000024891 symptom Diseases 0.000 description 10
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
235000014113 dietary fatty acids Nutrition 0.000 description 9
229930195729 fatty acid Natural products 0.000 description 9
239000000194 fatty acid Substances 0.000 description 9
150000004665 fatty acids Chemical class 0.000 description 9
238000007410 oral glucose tolerance test Methods 0.000 description 9
239000012071 phase Substances 0.000 description 9
238000012353 t test Methods 0.000 description 9
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
230000005526 G1 to G0 transition Effects 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
238000004611 spectroscopical analysis Methods 0.000 description 6
208000002705 Glucose Intolerance Diseases 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
238000004590 computer program Methods 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
238000005259 measurement Methods 0.000 description 5
201000009104 prediabetes syndrome Diseases 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000004885 tandem mass spectrometry Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
206010056997 Impaired fasting glucose Diseases 0.000 description 4
MSPCIZMDDUQPGJ-UHFFFAOYSA-N N-methyl-N-(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)N(C)C(=O)C(F)(F)F MSPCIZMDDUQPGJ-UHFFFAOYSA-N 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
238000000738 capillary electrophoresis-mass spectrometry Methods 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000009795 derivation Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
239000007789 gas Substances 0.000 description 4
238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
230000037353 metabolic pathway Effects 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
238000012545 processing Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
238000000009 pyrolysis mass spectrometry Methods 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
239000000758 substrate Substances 0.000 description 4
ANZCDFICXHXAOT-UHFFFAOYSA-N 2-oxopropanoic acid;propane-1,2,3-triol Chemical compound CC(=O)C(O)=O.OCC(O)CO ANZCDFICXHXAOT-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 3
QXKAIJAYHKCRRA-BXXZVTAOSA-N D-ribonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O QXKAIJAYHKCRRA-BXXZVTAOSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
238000004252 FT/ICR mass spectrometry Methods 0.000 description 3
BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
206010022489 Insulin Resistance Diseases 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
102000015636 Oligopeptides Human genes 0.000 description 3
108010038807 Oligopeptides Proteins 0.000 description 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
239000012491 analyte Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 3
235000000431 campesterol Nutrition 0.000 description 3
238000013375 chromatographic separation Methods 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
230000006870 function Effects 0.000 description 3
230000036541 health Effects 0.000 description 3
230000006698 induction Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
235000016709 nutrition Nutrition 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
238000002203 pretreatment Methods 0.000 description 3
229930010796 primary metabolite Natural products 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
230000004044 response Effects 0.000 description 3
229930000044 secondary metabolite Natural products 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
241000894007 species Species 0.000 description 3
238000002366 time-of-flight method Methods 0.000 description 3
238000011282 treatment Methods 0.000 description 3
INAPMGSXUVUWAF-QWBQGLJISA-N 1D-myo-inositol 2-phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](OP(O)(O)=O)[C@@H](O)[C@@H]1O INAPMGSXUVUWAF-QWBQGLJISA-N 0.000 description 2
QXPLWXHYPGWDIL-UHFFFAOYSA-N 2,3-dihydroxypropyl dihydrogen phosphate;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.OCC(O)COP(O)(O)=O QXPLWXHYPGWDIL-UHFFFAOYSA-N 0.000 description 2
FSSVRLXFJPQUTM-WCCKRBBISA-N 2-aminoacetic acid;(2s)-2-amino-4-methylsulfanylbutanoic acid Chemical compound NCC(O)=O.CSCC[C@H](N)C(O)=O FSSVRLXFJPQUTM-WCCKRBBISA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 2
QGWDGYSMGGJCNS-UHFFFAOYSA-N C(CCCCCCCCCCCCCCCC)(=O)O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O Chemical compound C(CCCCCCCCCCCCCCCC)(=O)O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O QGWDGYSMGGJCNS-UHFFFAOYSA-N 0.000 description 2
HAZNTXRVYHQPGD-JWTVCCRHSA-N C(CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC)(=O)O.N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC)(=O)O.N[C@@H](CC1=CC=CC=C1)C(=O)O HAZNTXRVYHQPGD-JWTVCCRHSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
INAPMGSXUVUWAF-UHFFFAOYSA-N D-myo-inositol 2-monophosphate Natural products OC1C(O)C(O)C(OP(O)(O)=O)C(O)C1O INAPMGSXUVUWAF-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
241000282412 Homo Species 0.000 description 2
108700011259 MicroRNAs Proteins 0.000 description 2
208000004880 Polyuria Diseases 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
235000007244 Zea mays Nutrition 0.000 description 2
240000008042 Zea mays Species 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000001133 acceleration Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
230000008512 biological response Effects 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
238000004422 calculation algorithm Methods 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
238000011157 data evaluation Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003914 insulin secretion Effects 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
239000011976 maleic acid Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
238000005191 phase separation Methods 0.000 description 2
USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 2
206010036067 polydipsia Diseases 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000005173 quadrupole mass spectroscopy Methods 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
229940086735 succinate Drugs 0.000 description 2
230000003319 supportive effect Effects 0.000 description 2
150000003505 terpenes Chemical class 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000032258 transport Effects 0.000 description 2
238000006227 trimethylsilylation reaction Methods 0.000 description 2
229940045136 urea Drugs 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
YNHBZSVYGIKALB-ZATYTLRZSA-N (2s)-2,5-diamino-5-oxopentanoic acid;(2s)-2,5-diaminopentanoic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(N)=O YNHBZSVYGIKALB-ZATYTLRZSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
BMGWZHWESYHXHC-UHFFFAOYSA-N 2-amino-3-methylpentanoic acid;2-amino-4-methylpentanoic acid Chemical compound CCC(C)C(N)C(O)=O.CC(C)CC(N)C(O)=O BMGWZHWESYHXHC-UHFFFAOYSA-N 0.000 description 1
FCIIQWPNYKLBHF-UHFFFAOYSA-N 2-aminoacetic acid;7,9-dihydro-3h-purine-2,6,8-trione Chemical compound NCC(O)=O.N1C(=O)NC(=O)C2=C1NC(=O)N2 FCIIQWPNYKLBHF-UHFFFAOYSA-N 0.000 description 1
206010061666 Autonomic neuropathy Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
UOCIVZOYKFBASZ-UHFFFAOYSA-N C(C(O)CO)(=O)O.C(CCC(=O)O)(=O)O Chemical compound C(C(O)CO)(=O)O.C(CCC(=O)O)(=O)O UOCIVZOYKFBASZ-UHFFFAOYSA-N 0.000 description 1
PUHIKLZLTGVSQF-WDBKTSHHSA-N C(CCCCCCCCCCCCCCC)(=O)O.N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound C(CCCCCCCCCCCCCCC)(=O)O.N[C@@H](CC1=CC=CC=C1)C(=O)O PUHIKLZLTGVSQF-WDBKTSHHSA-N 0.000 description 1
FSEOSJDPSWBXMK-UHFFFAOYSA-N CC(=O)C(O)=O.CCCCCCCCCCCCCCCCCC(O)=O Chemical compound CC(=O)C(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FSEOSJDPSWBXMK-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000938605 Crocodylia Species 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108091006149 Electron carriers Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
BQQKMAFEYBSBQW-UHFFFAOYSA-N NC(=O)N.C(CCCCCCCCCCCCC)(=O)O Chemical compound NC(=O)N.C(CCCCCCCCCCCCC)(=O)O BQQKMAFEYBSBQW-UHFFFAOYSA-N 0.000 description 1
MGXWIWTUOUFLQC-OMSMUOAWSA-N OCC(O)CO.N[C@@H](CC1=CC=CC=C1)C(=O)O.N1[C@@H](CCC1)C(=O)O Chemical compound OCC(O)CO.N[C@@H](CC1=CC=CC=C1)C(=O)O.N1[C@@H](CCC1)C(=O)O MGXWIWTUOUFLQC-OMSMUOAWSA-N 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
238000001069 Raman spectroscopy Methods 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
108020004566 Transfer RNA Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
DWDXPVOFUSZPIT-UHFFFAOYSA-N [S].C1=CC=C2NC=CC2=C1 Chemical class [S].C1=CC=C2NC=CC2=C1 DWDXPVOFUSZPIT-UHFFFAOYSA-N 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
150000001345 alkine derivatives Chemical class 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
235000010208 anthocyanin Nutrition 0.000 description 1
239000004410 anthocyanin Substances 0.000 description 1
229930002877 anthocyanin Natural products 0.000 description 1
150000004636 anthocyanins Chemical class 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000005251 capillar electrophoresis Methods 0.000 description 1
229940077731 carbohydrate nutrients Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
235000021466 carotenoid Nutrition 0.000 description 1
150000001747 carotenoids Chemical class 0.000 description 1
230000006652 catabolic pathway Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
239000005515 coenzyme Substances 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000013500 data storage Methods 0.000 description 1
101150047356 dec-1 gene Proteins 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003831 deregulation Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000012631 diagnostic technique Methods 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000000835 electrochemical detection Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000011152 fibreglass Substances 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
150000002215 flavonoids Chemical class 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
230000014101 glucose homeostasis Effects 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
125000004383 glucosinolate group Chemical group 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
230000034659 glycolysis Effects 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000000752 ionisation method Methods 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
229930013032 isoflavonoid Natural products 0.000 description 1
150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
235000012891 isoflavonoids Nutrition 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
229920005610 lignin Polymers 0.000 description 1
238000011068 loading method Methods 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000009120 phenotypic response Effects 0.000 description 1
229930015704 phenylpropanoid Natural products 0.000 description 1
125000001474 phenylpropanoid group Chemical group 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
230000005097 photorespiration Effects 0.000 description 1
230000029553 photosynthesis Effects 0.000 description 1
238000010672 photosynthesis Methods 0.000 description 1
229930001119 polyketide Natural products 0.000 description 1
125000000830 polyketide group Chemical group 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
150000004032 porphyrins Chemical class 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000009117 preventive therapy Methods 0.000 description 1
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
230000008569 process Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000004063 proteosomal degradation Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000029964 regulation of glucose metabolic process Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000035806 respiratory chain Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000012764 semi-quantitative analysis Methods 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
238000013517 stratification Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
238000007473 univariate analysis Methods 0.000 description 1
238000012800 visualization Methods 0.000 description 1
239000002699 waste material Substances 0.000 description 1
150000003735 xanthophylls Chemical class 0.000 description 1
235000008210 xanthophylls Nutrition 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pathology (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Bioinformatics & Computational Biology (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Spectroscopy & Molecular Physics (AREA)
Biophysics (AREA)
Investigating Or Analysing Biological Materials (AREA)
Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ES07727167T 2006-03-24 2007-03-21 Medios y método para predecir diabetes tipo ii. Active ES2358846T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP06111705		2006-03-24
EP06111705A EP1837657A1 (fr)	2006-03-24	2006-03-24	Moyens et procédé pour prédire ou diagnostiquer un diabète
EP06120273		2006-09-07

Publications (1)

Publication Number	Publication Date
ES2358846T3 true ES2358846T3 (es)	2011-05-16

Family

ID=36689463

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES07727167T Active ES2358846T3 (es)	2006-03-24	2007-03-21	Medios y método para predecir diabetes tipo ii.
ES07727168T Active ES2358454T3 (es)	2006-03-24	2007-03-21	Medios y método para predecir diabetes tipo ii.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES07727168T Active ES2358454T3 (es)	2006-03-24	2007-03-21	Medios y método para predecir diabetes tipo ii.

Country Status (3)

Country	Link
EP (1)	EP1837657A1 (fr)
CN (1)	CN101443663A (fr)
ES (2)	ES2358846T3 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009109647A1 (fr) *	2008-03-05	2009-09-11	Gunnar Norstedt	Procédé de surveillance d'un état métabolique par mesure de l'inositol phosphate
WO2009153136A2 (fr) *	2008-05-28	2009-12-23	Basf Se	Moyes et procédés d'estimation de la toxicité hépatique
WO2009153131A1 (fr) *	2008-05-28	2009-12-23	Basf Se	Moyens et procédés pour évaluer une induction enzymatique du foie
US20110311650A1 (en) *	2008-07-07	2011-12-22	Thomas Wang	Multiplexed biomarkers of insulin resistance
CN102565253A (zh) *	2010-12-16	2012-07-11	中国人民解放军第二军医大学	一种小分子代谢物图谱及其制作方法和用途
CN103403548A (zh) *	2010-12-23	2013-11-20	梅坦诺米克斯保健有限公司	用于预测糖尿病的工具和方法
CN106979982B (zh) *	2016-01-19	2021-01-05	上海市第六人民医院	一种用于糖尿病风险预测、治疗评价的方法及试剂盒
CN105911287A (zh) *	2016-04-06	2016-08-31	深圳市老年医学研究所	2型糖尿病脾虚证唾液蛋白指纹图谱分子诊断模型建立方法
SG11201810254UA (en) *	2016-05-17	2018-12-28	Univ Osaka	Blood sample analysis method and system, for determining diabetes
EP3401683A1 (fr) *	2017-05-10	2018-11-14	Eberhard Karls Universität Tübingen Medizinische Fakultät	Diagnostic de maladie métabolique par l'utilisation d'un biomarqueur
CN108169370B (zh) *	2017-12-19	2020-09-04	万舒（北京）医药科技有限公司	测定生物样品中丙酮酸乙酯及其代谢物丙酮酸的方法
CN108680546A (zh) *	2018-05-09	2018-10-19	盐城师范学院	一种用于测定d-3-羟基丁酸的试剂盒
CN113866285B (zh) *	2020-06-30	2024-07-09	上海脉示生物技术有限公司	用于糖尿病诊断的生物标志物及其应用
WO2023097510A1 (fr) *	2021-11-30	2023-06-08	江苏品生医疗科技集团有限公司	Marqueur permettant de prédire la probabilité pour un sujet de souffrir de diabète, et son utilisation
CN115356471A (zh) *	2022-08-17	2022-11-18	上海市内分泌代谢病研究所	天冬酰胺在预测或诊断2型糖尿病中的应用
WO2025133394A1 (fr) *	2023-12-22	2025-06-26	Maven Health Gmbh	Empreinte métabolique d'échantillons de salive par rmn

2006
- 2006-03-24 EP EP06111705A patent/EP1837657A1/fr not_active Withdrawn
2007
- 2007-03-21 ES ES07727167T patent/ES2358846T3/es active Active
- 2007-03-21 CN CNA2007800169198A patent/CN101443663A/zh active Pending
- 2007-03-21 ES ES07727168T patent/ES2358454T3/es active Active

Also Published As

Publication number	Publication date
EP1837657A1 (fr)	2007-09-26
ES2358454T3 (es)	2011-05-10
CN101443663A (zh)	2009-05-27

Publication	Publication Date	Title
ES2358846T3 (es)	2011-05-16	Medios y método para predecir diabetes tipo ii.
ES2525345T3 (es)	2014-12-22	Procedimiento de diagnóstico de diabetes de tipo II
JP5933432B2 (ja)	2016-06-08	前立腺癌を診断する手段と方法
AU2009259540B2 (en)	2015-11-05	Means and methods for assessing liver toxicity
CA2799032A1 (fr)	2012-01-05	Methodes de diagnostic des maladies du foie
AU2011346553A1 (en)	2013-07-11	Means and method for predicting diabetes
ES2688121T3 (es)	2018-10-31	Medios y procedimientos de diagnóstico de la reaparición de cáncer de próstata después de prostatectomía
JP2015042985A (ja)	2015-03-05	肝酵素誘導を評価する手段及び方法